Bladder disease resulting in cystectomy and urinary diversion Urological and Genital Diseases Acquired absence of other organs of urinary tract
Conditions
Interventions
According to the randomization, an equal number of patients will be allocated to receive the Ringerfundin® solution or the G5-K crystalloid solution as baseline infusion during the whole time that an
Sponsors
Bern University Hospital (Switzerland)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 years or over 2. Cystectomy with urinary diversion 3. American Society of Anaesthesiologists (ASA) classification II and III 4. Informed consent
Exclusion criteria
Exclusion criteria: 1. Pregnant, breastfeeding women (exclusion for surgery per se) 2. Congestive heart failure [New York Heart Association (NYHA) classification =3] 3. Hepatic disease (prothrombin ratio <50%) 4. Significant renal dysfunction (estimated glomerular filtration rate <45 ml/min)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| First defecation (return of bowel function) postoperatively | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. First flatus 2. Positive fluid balance (body weight difference postoperatively vs preoperatively) 3. Incidence of kidney function disorders according to the RIFLE classification 4. Difference in pH 24 h postoperatively (metabolic acidosis defined as hyperchloremia, normal anion gap, low plasma bicarbonate) 5. Changes in plasma and urine osmolality during the duration of infusion 6. Incidence of hypernatriemia during the duration of infusion 7. Incidence of hyperchloremia during the duration of infusion 8. Incidence of hypokaliemia during the duration of infusion 9. Changes in plasma renin, aldosterone, arginin vasopressin and brain natriuretic peptide (BNP) levels 10. Changes in neutrophil gelatinase-associated lipocalin (NGAL) urine values | — |
Countries
Switzerland
Outcome results
None listed